SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Clarity Pharmaceuticals’ Phase III Trial Reaches Participant Target

Clarity Pharmaceuticals says its registrational Phase III CLARIFY trial has reached its target number of participants.

Related stories